Abstracts tagged "juvenile SLE"

Abstract Number: 1736 • 2019 ACR/ARP Annual Meeting
Cognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus: Early Detection with MRI Spectroscopy and Its Association with MOG Antibodies
Huseyin Kilic ¹, Sezgin Sahin ², Mekiya Filiz Toprak ³, Gokce Hale Atay ⁴, Kubra Yilmaz ¹, Amra Adrovic ⁵, Kenan Barut ⁶, Esin Ozturk Isik ⁴, Erdem Tuzun ⁷, Osman Kizilkilic ⁸, Sema Saltik ¹ and Ozgur Kasapcopur⁹, ¹Department of Pediatric Neurology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ²Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ³Department of Pediatric Neurology, Bezmialem Vakif University, School of Medicine, Istanbul, Turkey, Istanbul, Turkey, ⁴Institute of Biomedical Engineering, Boğaziçi University, Istanbul, Turkey, Istanbul, Turkey, ⁵Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ⁶Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, ⁷Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, Istanbul, Turkey, ⁸Department of Neuroradiology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ⁹Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by the presence of various autoantibodies. Unnoticed and progressive cognitive impairment may develop in…
Abstract Number: 1741 • 2019 ACR/ARP Annual Meeting
Depression and Anxiety Symptoms in Childhood-Onset Systemic Lupus Erythematosus
Kate Neufeld¹, Frank Silverio ², Lawrence Ng ³, Ashley Danguecan ⁴, Daniela Dominguez ³, Reva Schachter ², Michelle Quilter ⁵, Julie Couture ⁶, Daphne Korczak ⁷, Deborah Levy ⁸, Linda Hiraki ⁹, Earl D. Silverman ¹⁰ and Andrea Knight ¹¹, ¹Division of Rheumatology, The Hospital For Sick Children, University of Toronto, Toronto, Canada, ²The Hospital for Sick Children, Toronto, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁴Division of Rheumatology and Dept of Psychology, The Hospital For Sick Children, Toronto, Canada, ⁵Department of Psychiatry,The Hospital For Sick Children, Toronto, Canada, ⁶The Hospital for Sick Children, Montreal, Canada, ⁷Dept of Psychiatry, SickKids and Dept of Psychiatry, University of Toronto, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ¹¹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Depression and anxiety disorders are common in patients with childhood-onset systemic lupus erythematosus (cSLE). It is unclear if they are due to central nervous…
Abstract Number: 1744 • 2019 ACR/ARP Annual Meeting
Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience
Ugo Awa¹, Marietta De Guzman ² and Eyal Muscal ³, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, ²Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Childhood-onset SLE (cSLE) is an autoimmune disease characterized by multiorgan involvement often necessitating a variety of immunolytic and immunomodulatory therapies to achieve adequate disease…
Abstract Number: 1748 • 2019 ACR/ARP Annual Meeting
Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood
Sara Patrizi¹, Douglas Stram ², Miranda Weintraub ³ and Alexandra Aminoff ¹, ¹Kaiser Permanente, Department of Pediatrics, Oakland, ²Kaiser Permanente Northern California, Division of Research, Oakland, ³Kaiser Permanente, Department of Graduate Medical Education, Oakland
Background/Purpose: Hydroxychloroquine (HCQ), a medication used to treat Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus (DLE) and Sjogren’s Syndrome (SS), reduces disease flare-ups, organ damage,…
Abstract Number: 1725 • 2019 ACR/ARP Annual Meeting
Disease Activity in Childhood-Onset Systemic Lupus Erythematosus: Initial Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Emily Smitherman¹, Mary Beth Son ², Andrea Knight ³, Timothy Beukelman ⁴, Jeffrey Curtis ¹ and Aimee Hersh ⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Boston Children's Hospital, Boston, MA, ³Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵University of Utah, Salt Lake City, UT
Background/Purpose: Substantial risk of early morbidity and mortality exists for patients with childhood-onset systemic lupus erythematosus (cSLE) despite widespread use of immunosuppressive therapy. There are…
Abstract Number: 1734 • 2019 ACR/ARP Annual Meeting
Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients
Anastasia-vasiliki Madenidou¹, Yasmin Mahfouz ², Oliver Cheng ², Farah El-Sharnouby ², Charlene Foley ² and Coziana Ciurtin ³, ¹Centre for Adolescent Rheumatology, University College London London, UK, LOndon, ²Centre for Adolescent Rheumatology, University College London London, UK, London, United Kingdom, ³Centre for Adolescent Rheumatology, University College London London, UK, Londond, United Kingdom
Background/Purpose: An estimated 10-20% of all patients with systemic lupus erythematosus (SLE) develop clinical disease before the age of 18 years and are therefore classified…
Abstract Number: 2867 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Hermine I. Brunner¹, Carlos Abud-Mendoza², Diego I. Viola³, Inmaculada Calvo⁴, Deborah M. Levy⁵, Julia Calderon Gallegos⁶, Manuel Ferrandiz⁷, Vyacheslav Chasnyk⁸, Vladmir Keltsev⁹, Jordi Anton¹⁰, Maria Paz¹¹, Michael Shishov¹², Alina Lucica Boteanu¹³, Michael Henrickson¹⁴, Damon Bass¹⁵, Kenneth Clark¹⁶, Anne Hammer¹⁵, Beulah Ji¹⁶, David Roth¹⁵, Herbert Struemper¹⁷, Mei-Lun Wang¹⁸, Alberto Martini¹⁹, Daniel J Lovell²⁰ and Nicola Ruperto¹⁹, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosy, Mexico, ³CAICI Institute, Rosario City, Santa Fe State, Argentina, ⁴Hospital Universitario La Fe, Valencia, Spain, ⁵Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁶Instituto de Ginecologia y Reproduccion, Santiago De Surco, Peru, ⁷Instituto Nacional de Salud del Nino, Lima, Peru, ⁸St Petersburg State Pediatric Medical Academy, St Petersburg, Russian Federation, ⁹City Clinical Hospital No.5, Tolyatti, Russian Federation, ¹⁰SJD Barcelona Children’s Hospital, Barcelona, Spain, ¹¹Clinica Anglo Americana, Lima, Peru, ¹²Phoenix Children's Hospital, Phoenix, AZ, ¹³University Hospital Ramón y Cajal, Madrid, Spain, ¹⁴Cincinnati Children’s Medical Center, Cincinnati, OH, ¹⁵GlaxoSmithKline, Philadelphia, PA, ¹⁶GlaxoSmithKline, Stevenage, United Kingdom, ¹⁷GlaxoSmithKline, Research Triangle Park, NC, ¹⁸GlaxoSmithKline, Collegeville, PA, ¹⁹Universita di Genova Pediatria II, Genova, Italy, ²⁰Cincinnati Children's Medical Center, Cincinnati, OH
Background/Purpose: Belimumab (BEL) is approved in adults with active systemic lupus erythematosus (SLE). There are no approved biologic therapies for pediatric patients with childhood-onset SLE…
Abstract Number: 369 • 2017 ACR/ARHP Annual Meeting
Hepatitis A Virus Vaccination in Juvenile-Onset Systemic Lupus Erythematosus
Sevinc Mertoglu¹, Sezgin Sahin¹, Omer Faruk Beser², Amra Adrovic¹, Kenan Barut¹, Pelin Yuksel³, Soner Sazak⁴, Bekir Kocazeybek⁵ and Ozgur Kasapcopur¹, ¹Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ²Pediatric Gastroenterology, Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Turkey, ³Microbiology, Istanbul University, Cerrahpasa Medical School, Department of Microbiology, Istanbul, Turkey, ⁴Pediatrics, Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical School, Department of Microbiology, Istanbul, Turkey
Background/Purpose: Various infections play significant roles in flares of systemic lupus erythematosus (SLE). Hepatitis A virus is one of these infectious agents that has high…
Abstract Number: 2027 • 2017 ACR/ARHP Annual Meeting
Pre-Visit Planning Improves Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematosus
Kelly Wise¹, Fatima Barbar-Smiley², Stephanie Lemle², Darby MacDonald², Ohoud AlAhmed³, Evan Mulvihill⁴, William Cotton², Monica Ardura², Cagri Yildirim-Toruner⁵ and Vidya Sivaraman^6,7, ¹Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Pediatrics, Nationwide Children's Hospital, Columbus, OH, ⁴Pediatrics and Rheumatology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁵Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁶Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁷Pediatrics, The Ohio State University, COLUMBUS, OH
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) lupus are up to 13 times more likely to develop invasive pneumococcal infections, resulting in increased morbidity and…
Abstract Number: 2975 • 2017 ACR/ARHP Annual Meeting
Using Immune and Metabolic Phenotyping to Understand the Immunopathogenesis of Juvenile-Onset SLE and Stratify Patient Groups
George Robinson¹, Marsilio Adriani¹, Ines Pineda Torra², Yiannis Ioannou³ and Elizabeth Jury⁴, ¹Centre for Rheumatoloy Research, University College London, London, United Kingdom, ²Centre for Clinical Pharmacology, University College London, London, United Kingdom, ³Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterized by immune cell dysregulation, chronic inflammation and increased cardiovascular risk. Disease onset dominates mid-puberty…
Abstract Number: 1430 • 2016 ACR/ARHP Annual Meeting
Adherence to the International Consensus Quality Indicators for Longitudinal Health Maintenance and Preventative Care in a Pediatric Rheumatology Clinic
Abigail Bosk, Barbara Edelheit, Lawrence Zemel and Heather Tory, Rheumatology, Connecticut Children's Medical Center, Hartford, CT
Background/Purpose: Juvenile systemic lupus erythematosus (jSLE) is a chronic disease associated with significant morbidity. Variability in the health maintenance-related management of these patients can contribute…
Abstract Number: 389 • 2015 ACR/ARHP Annual Meeting
Clinical and Serological Differences Between Juvenile-Onset and Adult-Onset Systemic LUPUS Erythematosus Patients from a National Registry of Patients
TC Salman-Monte¹, V Torrente-Segarra², I Rúa-Figueroa³, J Calvo-Alen^4,5, FJ Lopez Longo^6,7, M Galindo^8,9 and JM Pego-Reigosa¹⁰, ¹Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, ²Rheumatology, Hospital General Hospitalet-Moisès Broggi, Hospitalet Llobregat, Spain, ³Rheumatology, Hospital de GC Dr Negrin, Las Palmas GC, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ⁶Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁸Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ¹⁰Rheumatology, EOXI Vigo, Vigo, Spain
Background/Purpose: To assess clinical and serological differences between patients with juvenile-onset systemic lupus erythematosus (jSLE) and adult-onset (aSLE) from a National database.Methods: Data included in…
Abstract Number: 403 • 2015 ACR/ARHP Annual Meeting
Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?
Justin Hung Tiong Tan¹, Sook Fun Hoh², Manasita Tanya¹, Lena Das¹, Ma Thin Mar Win³, Yiong Huak Chan³ and Thaschawee Arkachaisri^1,4, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ³Biostatistics Unit, Yong Loo Lin School of Medicine, Singapore, Singapore, ⁴Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore
Background/Purpose: The time to recovery from proteinuria in patients with lupus nephritis (LN) receiving standard treatment has been described in adult, but not in children.…
Abstract Number: 2468 • 2015 ACR/ARHP Annual Meeting
Antibodies to Histocompatibility Antigens in Juvenile Systemic Lupus Erythematosus Patients
Ana L Rodríguez-Lozano¹, Anne M. Stevens², Jessica M Foster³, Marisa S. Klein-Gitelman⁴, Hermine I. Brunner⁵, Elizabeth Field⁶, Ann M Reed⁷ and Karen Onel⁸, ¹Immunology, Instituto Nacional de Pediatria, Mexico City, Mexico, ²Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA, ³Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ⁴Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Internal Medicine, University of Iowa, Iowa City, IA, ⁷Department of Pediatrics, Duke University, Durham, NC, ⁸Pediatric Rheumatology, Univ of Chicago, Chicago, IL
Background/Purpose: Microchimerism with HLA mismatched maternal cells can be readily demonstrated in normal individuals and is now established as a normal biological phenomenon. Pediatric SLE…
Abstract Number: 2662 • 2014 ACR/ARHP Annual Meeting
Attribution Protocol and Clinical Significance of Neuropsychiatric Manifestations in Childhood-Onset Systemic Lupus Erythematosus
Renata Barbosa¹, Karina Oliveira Peliçari², Aline T. Lapa³, Nailu A. Sinicato³, Mariana Postal³, Roberto Marini⁴, Marcelo Govoni Sr.⁵ and Simone Appenzeller⁶, ¹Medicine, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Germany, ²State University of Campinas, Campinas, Brazil, ³Medicine, State University of Campinas, Campinas, Brazil, ⁴Departament of Pediatrics, State University of Campinas, Campinas, Brazil, ⁵Department of Clinical medicine and Experimental, University of Ferrara, Ferrara, Italy, ⁶Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is caused by an imbalance of the immune system and may lead to injury and dysfunction of various systems and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].